ATE552861T1 - Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren - Google Patents

Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren

Info

Publication number
ATE552861T1
ATE552861T1 AT08729335T AT08729335T ATE552861T1 AT E552861 T1 ATE552861 T1 AT E552861T1 AT 08729335 T AT08729335 T AT 08729335T AT 08729335 T AT08729335 T AT 08729335T AT E552861 T1 ATE552861 T1 AT E552861T1
Authority
AT
Austria
Prior art keywords
methods
amphetamine
stimulants
production
polar hydrophilic
Prior art date
Application number
AT08729335T
Other languages
English (en)
Inventor
Travis C Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Application granted granted Critical
Publication of ATE552861T1 publication Critical patent/ATE552861T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT08729335T 2007-02-08 2008-02-08 Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren ATE552861T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88887007P 2007-02-08 2007-02-08
PCT/US2008/053363 WO2008098151A2 (en) 2007-02-08 2008-02-08 Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same

Publications (1)

Publication Number Publication Date
ATE552861T1 true ATE552861T1 (de) 2012-04-15

Family

ID=39591454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08729335T ATE552861T1 (de) 2007-02-08 2008-02-08 Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren

Country Status (9)

Country Link
US (4) US7772222B2 (de)
EP (3) EP2109465B1 (de)
JP (1) JP2010518113A (de)
CN (1) CN101631566A (de)
AT (1) ATE552861T1 (de)
AU (1) AU2008213643A1 (de)
BR (1) BRPI0807157A2 (de)
CA (1) CA2674020A1 (de)
WO (1) WO2008098151A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CN101594778A (zh) * 2006-12-11 2009-12-02 凯姆制药公司 苯丙胺的非标准氨基酸结合物及其制备和使用的方法
EP2109465B1 (de) * 2007-02-08 2012-04-11 Kempharm, Inc. Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren
US8614346B2 (en) 2009-06-19 2013-12-24 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
US8779191B2 (en) 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
CA3123900A1 (en) 2011-07-28 2013-01-31 Kempharm Inc. Methylphenidate-prodrugs, processes of making and using the same
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
WO2013019187A1 (en) * 2011-07-29 2013-02-07 Kempharm, Inc. Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
US20160008334A1 (en) * 2013-03-05 2016-01-14 Requis Pharmaceuticals Inc. Preparations for the Treatment of Sleep-Related Respiratory Disorders
WO2014144115A1 (en) * 2013-03-15 2014-09-18 Shire Llc Fixed dose combination treatment for schizophrenia
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN104833743B (zh) * 2015-05-18 2016-10-26 公安部物证鉴定中心 一种液质联用分析生物样品中卡西酮、甲卡西酮、4-甲基甲卡西酮的方法
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2018107132A1 (en) 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
US20200114014A1 (en) * 2017-04-11 2020-04-16 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Amide and Imide Prodrugs of Amphetamine Compounds and Uses Thereof
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
CN109187832B (zh) * 2018-09-30 2021-07-30 华润三九医药股份有限公司 Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法
WO2020181000A1 (en) * 2019-03-06 2020-09-10 Ensysce Biosciences, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
JP2023505687A (ja) 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド 癌の処置方法
CN111410622A (zh) * 2020-04-13 2020-07-14 康化（上海）新药研发有限公司 L-胱硫醚盐酸盐的合成方法
EP4211130A1 (de) * 2020-09-11 2023-07-19 COMPASS Pathfinder Limited Neue safridaminderivate mit prodrug-eigenschaften
CA3199184A1 (en) * 2020-11-18 2022-05-27 Felix Lustenberger Mdma prodrugs to assist psychotherapy
MX2023010506A (es) 2021-03-09 2023-09-20 Ensysce Biosciences Inc Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos.
KR20240045222A (ko) * 2021-07-07 2024-04-05 테란 바이오사이언시스 인코포레이티드 3,4-메틸렌다이옥시메스암페타민 및 관련 환각제, 그리고 이들의 용도
CA3230025A1 (en) 2021-09-29 2023-04-06 Lynn Kirkpatrick Enzyme-cleavable methadone prodrugs and methods of use thereof
US20230202998A1 (en) 2021-11-17 2023-06-29 Terran Biosciences, Inc. Phenethylamine compounds salts, polymorphic forms and methods of use thereof
AU2023288496A1 (en) * 2022-06-25 2025-01-16 Definium Therapeutics US, Inc. R-mdma crystal forms
US20260085036A1 (en) * 2022-09-12 2026-03-26 Mihkal Gmbh Novel nootropic prodrugs of henethylamine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE539185A (de) * 1954-06-28
US2881113A (en) * 1957-01-29 1959-04-07 Ortho Pharma Corp Therapeutically active compositions containing amphetamines
US2892753A (en) * 1957-02-26 1959-06-30 Boehringer Sohn Ingelheim Central nervous system stimulant
DK1685839T3 (da) * 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
AU6528400A (en) * 1999-08-23 2001-03-19 David M. Ockert Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
EP1292307A2 (de) * 2000-06-09 2003-03-19 The Regents of The University of California Behandlung von schmerz mit nalbuphin und opioid antagonisten
US6417184B1 (en) * 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
AU2003219863C1 (en) 2002-02-22 2009-03-05 Shire Llc Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
EP1613261A4 (de) * 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
KR101159477B1 (ko) * 2003-05-29 2012-07-02 샤이어 엘엘씨 남용 방지성 암페타민 화합물
EP1931357A2 (de) * 2005-09-13 2008-06-18 Shire LLC Prodrugs von phentermin
CN101594778A (zh) 2006-12-11 2009-12-02 凯姆制药公司 苯丙胺的非标准氨基酸结合物及其制备和使用的方法
EP2109465B1 (de) * 2007-02-08 2012-04-11 Kempharm, Inc. Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren

Also Published As

Publication number Publication date
WO2008098151A2 (en) 2008-08-14
EP2433655A2 (de) 2012-03-28
US20080207757A1 (en) 2008-08-28
US20100292337A1 (en) 2010-11-18
WO2008098151A3 (en) 2008-12-31
EP2109465B1 (de) 2012-04-11
US20090239949A1 (en) 2009-09-24
US20110213034A1 (en) 2011-09-01
CN101631566A (zh) 2010-01-20
CA2674020A1 (en) 2008-08-14
BRPI0807157A2 (pt) 2014-04-29
EP2433655A3 (de) 2013-05-15
JP2010518113A (ja) 2010-05-27
EP2109465A2 (de) 2009-10-21
EP2433654A3 (de) 2013-05-15
US7772222B2 (en) 2010-08-10
AU2008213643A1 (en) 2008-08-14
EP2433654A2 (de) 2012-03-28

Similar Documents

Publication Publication Date Title
WO2008098151A3 (en) Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
ATE509622T1 (de) Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren
MA52544A (fr) Instrument d'agrafage chirurgical avec détachement d'arbre d'actionnement
TW200734314A (en) Piperazine compounds having herbicidal action
WO2011023582A3 (de) Verwendung von 1,3-diolen als biozide
BRPI0720355B8 (pt) Composições oftálmicas para o tratamento de presbiopia, bem como o uso das mesmas
WO2008122375A3 (en) Insecticidal aryl isoxazoline derivatives
ECSP10010014A (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
BRPI0717753A2 (pt) Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
WO2008092836A3 (en) Method for improving plant health
EA201001024A1 (ru) Обработка растений банана и картофеля с помощью новой противогрибковой композиции
HRP20080098T3 (en) Cutting element structure for garden trimmer
EP2120567A4 (de) Prodrugs von substituierten 1,3-dioxanen und ihre verwendungen
ATE548310T1 (de) Spaltfreudiges klebeband, seine verwendung und verwendung eines werkzeuges zu seiner herstellung
EA200702253A1 (ru) Фармацевтическая композиция
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
WO2009018551A3 (en) Therapeutic compounds
FR2893225B1 (fr) Pieu de goutteur d'irrigation.
JP2008519810A5 (de)
ITTO20050241A1 (it) Impianto dentario intraosseo.
MY146622A (en) N-phenylpyrazole derivatives as pesticides
JP2009143907A5 (de)
MX2022005012A (es) Compuestos, composiciones de d-anfetamina, y procedimientos para fabricar y utilizar los mismos.
UY29980A1 (es) Nuevas combinaciones de productos activos, comprendiendo un derivado de oximéter y un bis-tiocarbamato, procedimientos de preparación y aplicaciones.
WO2009141065A3 (de) (1,2-benzisothiazol-3-yl)(thio)carbamate und (1,2-benzisothiazol-3-yl)(thio)oxamate und deren oxidationsformen als pestizide